Efficacy and safety of infliximab in psoriatic patients over the age of 65

Andrea Chiricozzi, Athanasios Pavlidis, Annunziata Dattola, Luca Bianchi, Maria Sole Chimenti, Monika Fida, Rosita Saraceno

Risultato della ricerca: Contributo in rivistaArticolo in rivista

13 Citazioni (Scopus)


Background: Clinical data on the long-term safety and efficacy of infliximab on psoriatic patients who are older than 65 years are limited. Objectives: The aim is to report the long-term efficacy, safety and tolerance of infliximab in geriatric patients. Methods: This was a retrospective study conducted at the Department of Dermatology of the University of Rome Tor Vergata. Clinical data were reported at week 12, 52, 104, 208. Results: 151 charts were evaluated. A total of 27 patients were included. Range of the age was between 65 and 85 years; mean age was 73 years ±5.4; female to male ratio was 1:2; mean age of onset of psoriasis was 43 years±17. The average of treatment duration was 39 months ±27 (range 1–100). Fourteen patients suffered from plaque type psoriasis and 13 from psoriatic arthritis. At the baseline the mean PASI score was 15.6 ± 10.2. At week 12, 52, 104, and 208 the mean PASI was 2, 2.3, 1.9 and 1.8 respectively. A reduction in the mean PASI was maintained in the long-term treatment in 12 patients (p < 0.001). Conclusion: Our data suggest that long-term treatment with infliximab is effective and safe in patients over 65 years old and that IV therapy is also associated with a high compliance.
Lingua originaleEnglish
pagine (da-a)1459-1462
Numero di pagine4
RivistaExpert Opinion on Drug Safety
Stato di pubblicazionePubblicato - 2016


  • Age Factors
  • Aged
  • Aged, 80 and over
  • Arthritis, Psoriatic
  • Dermatologic Agents
  • Female
  • Humans
  • Infliximab
  • Italy
  • Male
  • Pharmacology (medical)
  • Psoriasis
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome
  • elderly
  • infliximab
  • long-term


Entra nei temi di ricerca di 'Efficacy and safety of infliximab in psoriatic patients over the age of 65'. Insieme formano una fingerprint unica.

Cita questo